Filtered By:
Specialty: Cardiology
Drug: Plavix

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 545 results found since Jan 2013.

Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials
In addition to risk‐factor modification, antithrombotic therapy is the hallmark of management to reduce cardiovascular ischemic events in patients with peripheral artery disease (PAD). Currently, the guidelines recommend long‐term antiplatelet therapy with aspirin or clopidogrel in this patient population to reduce myocardial infarction, stroke, and vascular death. Past outcomes studies have shown some benefit of ticagrelor, another antiplatelet agent, as compared with clopidogrel in patients with coronary disease and concomitant PAD. However, most recently, the Examining Use of Ticagrelor in Peripheral Artery Disease ...
Source: Clinical Cardiology - January 22, 2018 Category: Cardiology Authors: Rachael Ward, Chandler Long, Manesh R. Patel, William S. Jones Tags: REVIEW Source Type: research

Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
CONCLUSIONS: LAAC followed by DAPT seems to be a safe and efficient alternative for stroke prevention in patients with NVAF and contraindications to anticoagulation therapy. This strategy may provide a significant reduction of events such as stroke and bleeding versus the score-predicted rate. PMID: 29350390 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - January 19, 2018 Category: Cardiology Authors: Maksym J, Mazurek T, Kochman J, Grygier M, Kapłon-Cieślicka A, Marchel M, Lodziński P, Piątkowski R, Wilimski R, Czub P, Fojt A, Karolczak N, Hendzel P, Opolski G Tags: Kardiol Pol Source Type: research

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Conclusions These data from real-world observations demonstrate a higher risk for cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus alternative therapy is prescribed. A future randomized study of genotype-guided antiplatelet therapy may be of value.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 15, 2018 Category: Cardiology Authors: Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., Pratt, V. M., Alestock, T. D., Anderson, R. D., Alsip, J., Ardati, A. K., Brott, B. C., Brown, L., Ch Tags: Coronary Source Type: research

Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis Pharmacology
Conclusions— Across trials of cardiovascular and cerebrovascular disease, extended-duration clopidogrel on a background of aspirin has no overall effect on mortality or cancer but does reduce rates of myocardial infarction and stroke and increase rates of bleeding. These findings emphasize the need for selective use of extended clopidogrel therapy in patients in whom the risks of ischemia are not fully counterbalanced by the risks of bleeding.
Source: Circulation: Cardiovascular Interventions - January 8, 2018 Category: Cardiology Authors: Elmariah, S., Doros, G., Benavente, O. R., Bhatt, D. L., Connolly, S. J., Yusuf, S., Steinhubl, S. R., Liu, Y., Hsieh, W.-H., Yeh, R. W., Mauri, L. Tags: Pharmacology, Meta Analysis, Mortality/Survival Source Type: research

Impact of diabetes on benefit of switching dual antiplatelet therapy after acute coronary syndrome: A subanalysis of the TOPIC randomized study
Conclusion Switching DAPT proved its benefit after ACS in terms of bleeding prevention. However, in diabetic patients switching DAPT was associated with excess of ischemic events despite bleeding prevention. Switching DAPT strategy should be preferred in non-diabetic patients.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

Risk factors for the primary effectiveness endpoint in secondary prevention of acute coronary syndrome with antiplatelet agents: A cohort in the nationwide French claims and hospitalisation database
Conclusions In this nationwide real-life study, the risk factor most associated with the primary effectiveness endpoint was a Charlson comorbidity index>5.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (Timing Of Platelet Inhibition after acute Coronary Syndrome) randomized study
Conclusion A switched DAPT is superior to an unchanged DAPT strategy to prevent bleeding complications without increase in ischemic events following ACS.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy
Conclusion In ‘real-life’ ACS undergoing PCI, diabetic patients have higher – although not significantly – MACE rate and no difference in bleeding events. This difference in MACE was significant among clopidogrel-treated patients, whereas when newer antiplatelet agents were used the negative impact of DM on ischemic events was eliminated.
Source: Coronary Artery Disease - January 1, 2018 Category: Cardiology Tags: Original Research Source Type: research

Simplified percutaneous closure of patent foramen ovale and atrial septal defect with use of plain fluoroscopy: Single operator experience in 110 consecutive patients.
CONCLUSION: Percutaneous placement of an Amplatzer occluder was safe and effective with use of local anesthesia and fluoroscopy alone. There were no recurrent strokes over >4 years. Migraine relief was reported by >80% of patients. PMID: 29455783 [PubMed - in process]
Source: Indian Heart J - January 1, 2018 Category: Cardiology Authors: Manolis AS, Koulouris S, Rouska E, Pyrros J Tags: Indian Heart J Source Type: research

Associations between Complex PCI and Prasugrel or Clopidogrel use in Patients with Acute Coronary Syndromes undergoing PCI: From the PROMETHEUS Study
Conclusions Despite the use of contemporary techniques, ACS patients undergoing complex PCI had significantly higher rates of 1-year MACE. Adjusted magnitude of treatment effects with prasugrel versus clopidogrel were consistent in complex and non-complex PCI without evidence of interaction. Teaser In this analysis from the PROMETHEUS ACS registry (n = 19,914), complex PCI (PCI of left main/ bifurcation/ moderate-severely calcified lesion/ stent length ≥30mm) was associated with greater risk of 1-year MACE (death, myocardial infarction, stroke or unplanned revascularization; HR 1.29 [1.20-1.39]). Treatment effects with p...
Source: Canadian Journal of Cardiology - December 27, 2017 Category: Cardiology Source Type: research

Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy
Conclusion In ‘real-life’ ACS undergoing PCI, diabetic patients have higher – although not significantly – MACE rate and no difference in bleeding events. This difference in MACE was significant among clopidogrel-treated patients, whereas when newer antiplatelet agents were used the negative impact of DM on ischemic events was eliminated.
Source: Coronary Artery Disease - December 19, 2017 Category: Cardiology Tags: Original Research Source Type: research

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical endpoints - Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)
Conclusion The ICPC aims to identify new loci influencing clopidogrel efficacy by using state-of-the-art genetic techniques in a large cohort of clopidogrel-treated patients in order to better understand the genetic basis of on-treatment response variability.
Source: American Heart Journal - December 18, 2017 Category: Cardiology Source Type: research

Predictors of Mortality in Patients with Atrial Fibrillation (From the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ACTIVE a)
The mortality rate of most patients with atrial fibrillation (AF) exceeds the stroke rate, but predictors of mortality have not been well defined. The Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE) recruited AF patients who were unsuitable to receive vitamin K-antagonists and were randomized to aspirin alone vs. aspirin plus clopidogrel. We investigated independent predictors of all-cause mortality by multivariable Cox regression analysis and explored interactions with assigned antiplatelet therapy.
Source: The American Journal of Cardiology - December 11, 2017 Category: Cardiology Authors: Kanjana S. Perera, Lesly A. Pearce, Mukul Sharma, Oscar Benavente, Stuart J. Connolly, Robert G. Hart, ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators Source Type: research

Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis
Conclusions The effect of more potent P2Y12 inhibitors compared with clopidogrel on efficacy and safety end points is consistent in elderly and younger patients. These data imply that potent P2Y12 inhibitors should not be withheld from eligible patients solely because of advanced age.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research

Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications
AbstractPurpose of ReviewPlatelets are activated upon interaction with injured vascular endothelium to form a primary hemostatic plug. Pathogenic thrombosis driven by platelet aggregation can occur in the setting of vascular disease leading to ischemic events. The use of antiplatelet agents has become a mainstay for prevention of the secondary complications of vascular disease. This review summarizes seminal and recent literature related to this area.Recent FindingsAspirin is a cornerstone of antiplatelet therapy for coronary artery disease and cerebrovascular disease for prevention of myocardial infarction, stroke, and va...
Source: Current Atherosclerosis Reports - November 4, 2017 Category: Cardiology Source Type: research